Obstructive Sleep Apnea / Obesity Hypoventilation Syndrome

OSA: repetitive upper airway collapse during sleep; OHS: daytime hypoventilation (PaCO2 >45) in obese patients — both cause hypercapnic respiratory failure when decompensated

Symptoms / Associated Sx

  • OSA: Loud snoring, witnessed apneas, gasping/choking episodes at night, excessive daytime sleepiness (Epworth >10), morning headaches, nocturia, dry mouth

  • OHS: Excessive daytime sleepiness, morning headaches, dyspnea on exertion, peripheral edema (cor pulmonale), plethora/cyanosis, BMI >30 (usually >40)

  • Hypertension (resistant hypertension — OSA is a secondary cause)

  • Right heart failure signs in severe OHS: JVD, peripheral edema, elevated JVP

  • Polycythemia (chronic hypoxia)

Denies

  • Normal BMI without snoring history (reduces OSA likelihood — though can occur in non-obese patients)

  • Daytime PaCO2 normal (rules out OHS — OHS requires daytime hypercapnia, not just nocturnal)

  • No witnessed apneas or partner-reported symptoms (reduces OSA likelihood — though many sleep alone)

Social History (SHx)

BMI (obesity — primary risk factor for OHS), neck circumference >40 cm (men) / >35 cm (women), alcohol/sedative use (relaxes pharyngeal muscles), prior CPAP/BiPAP compliance, driving habits (sleepiness and driving — safety concern), mood symptoms (depression association with OSA), prior sleep study results.

Main Etiology

  • OSA: Upper airway anatomic narrowing (obesity, macroglossia, tonsillar hypertrophy, retrognathia) + pharyngeal muscle hypotonia during sleep → repetitive apneas/hypopneas → arousal → sleep fragmentation → EDS

  • OHS: Mechanical ventilatory restriction (obesity-related chest wall load) + reduced central ventilatory drive to CO2 (leptin resistance + load compensation failure) → daytime hypercapnia; OSA co-exists in ~90% of OHS patients

  • Severity: OSA classified by AHI (apnea-hypopnea index per hour) — mild 5–15; moderate 15–30; severe >30

Most Common DDx

  • COPD-related hypercapnia (smoking history; FEV1 <50%; emphysematous changes; no obesity-predominant; spirometry distinguishes)

  • Central sleep apnea (Cheyne-Stokes breathing in CHF; periodic breathing; no upper airway obstruction; treated differently — adaptive servo-ventilation)

  • Hypothyroidism (hypercapnia + fatigue + weight gain; TSH very elevated; reverses with thyroid hormone — always check TSH in OHS)

  • Neuromuscular disease causing nocturnal hypoventilation (ALS, MG, phrenic nerve palsy — NIF reduced; no upper airway obstruction; EMG/NCS distinguishes)

  • Upper airway resistance syndrome (snoring + arousals + EDS but AHI <5; esophageal pressure monitoring shows increased effort; treated similarly to OSA)

  • Narcolepsy (excessive daytime sleepiness without apneas; cataplexy; positive MSLT; HLA DQB1*0602 association)

DATA

  • Polysomnography (PSG — gold standard for OSA diagnosis; measures AHI, oxygen desaturation index, arousal index)

  • Home sleep apnea testing (HSAT) — acceptable for uncomplicated OSA suspicion; less sensitive for OHS/central apnea

  • ABG during wakefulness (OHS diagnosis requires daytime PaCO2 >45; SpO2 often low on room air)

  • Serum bicarbonate (elevated chronically from CO2 compensation — useful screening for OHS in obese patients; HCO3 >27 mEq/L → likely OHS)

  • Pulmonary function tests (rule out obstructive or restrictive lung disease)

  • CBC (polycythemia from chronic hypoxia)

  • TSH (hypothyroidism — always rule out)

  • Echo (pulmonary hypertension, RV dysfunction, tricuspid regurgitation — cor pulmonale in OHS)

  • Epworth Sleepiness Scale (subjective daytime sleepiness — score >10 = excessive)

  • STOP-BANG questionnaire (screening tool: Snoring, Tired, Observed apneas, hyPertension, BMI >35, Age >50, Neck >40, Gender male — ≥3 = high risk OSA)

Home Meds

  • Current CPAP/BiPAP settings (assess compliance; download data — AHI on therapy, leak rate, usage hours)

  • Sedatives, opioids, alcohol (worsen upper airway tone — minimize/eliminate)

  • Stimulants (modafinil, armodafinil — for residual EDS on CPAP; assess)

  • Diuretics (OHS with cor pulmonale — assess dose)

Plan

  • Acute decompensation (OHS with hypercapnic respiratory failure):

    • BiPAP immediately (IPAP 16–22 cmH2O, EPAP 8–10 cmH2O or titrated); AVAPS mode preferred for OHS (volume-assured)

    • Target SpO2 88–92% in CO2 retainers; allow CO2 to normalize over hours, not acutely

    • Avoid sedating medications

    • See Acute Respiratory Failure Requiring BiPAP section for full management

  • Definitive OSA management:

    • CPAP (first-line): 5–20 cmH2O (auto-titrating CPAP preferred — adjusts to upper airway resistance); titrated by sleep study

    • BiPAP (if CPAP failed or OHS): IPAP 16–22, EPAP 8–10 cmH2O; AVAPS for OHS

    • Oral appliance (mandibular advancement device — mild-moderate OSA or CPAP-intolerant)

    • Positional therapy (mild OSA — avoid supine position)

    • Surgical: UPPP (uvulopalatopharyngoplasty) — modest benefit; hypoglossal nerve stimulator (Inspire device — FDA approved for moderate-severe OSA with CPAP failure)

  • OHS-specific:

    • Nocturnal BiPAP/AVAPS is the cornerstone — improves daytime CO2 over weeks to months

    • Weight loss (most effective long-term intervention — bariatric surgery if BMI >35 + comorbidities; 20–30 kg weight loss can resolve OHS)

    • Medroxyprogesterone (respiratory stimulant — modest benefit; not first-line)

  • Cor pulmonale in OHS:

    • BiPAP (primary treatment — reverses pulmonary hypertension with adequate ventilation)

    • Diuretics (furosemide 40–80 mg PO daily) for fluid overload

    • Phlebotomy if Hct >55% (polycythemia causing hyperviscosity)

    • Avoid pulmonary vasodilators (sildenafil) in OHS — may worsen ventilation-perfusion mismatch

  • Driving counseling (severe OSA + EDS → increased accident risk; restrict driving until treated)

  • Alcohol and sedative avoidance; weight loss counseling

  • Sleep medicine consult; respiratory therapy for CPAP/BiPAP education and mask fitting

  • Trend ABG, bicarbonate, SpO2; echo (pulmonary hypertension response to BiPAP)

  • PT/OT — mobility; weight management program

  • Discharge: CPAP/BiPAP prescription with auto-titrating settings; sleep medicine follow-up within 2–4 weeks; CPAP compliance data review at follow-up; weight loss program; driving restriction counseling until AHI controlled; PCP for comorbidity management (HTN, diabetes)

Red Flags

  • Daytime PaCO2 >50 + pH <7.35 (OHS decompensation) → ICU-level monitoring; BiPAP immediately

  • Severe cor pulmonale + OHS (right heart failure) → diuresis + BiPAP; avoid O2 alone (worsens CO2 retention without addressing hypoventilation)

  • OSA + resistant hypertension not responding to 3 antihypertensives → always check CPAP compliance; untreated OSA is a secondary cause of resistant HTN

  • Polycythemia vera-like picture in obese patient → rule out OHS before assuming primary PV; ABG and erythropoietin level distinguish

  • Perioperative period in OSA/OHS patient → highest risk for post-operative respiratory failure; CPAP/BiPAP mandatory post-op; avoid oversedation

Senior IM Resident Pearls

  • Serum bicarbonate >27 mEq/L in an obese patient → high sensitivity for OHS (~85%); cost-effective screening; confirm with daytime ABG

  • OSA is the most common correctable cause of resistant hypertension — always ask about snoring/apneas in hypertensive patients not responding to 3 agents; CPAP reduces blood pressure by 2–5 mmHg (modest but meaningful in resistant HTN)

  • OHS and COPD coexist in "overlap syndrome" — these patients have worse outcomes than either condition alone; BiPAP is preferred over CPAP; target SpO2 88–92%

  • AVAPS (average volume-assured pressure support) — pressure varies automatically to deliver a set tidal volume; superior to fixed BiPAP in OHS; reduces CO2 more effectively over time

  • Common mistake: Treating OHS with O2 alone — O2 alone in an OHS patient increases SpO2 but does not address the hypoventilation; CO2 rises further; always use BiPAP/CPAP as primary treatment